
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (13): 1559-1567.DOI: 10.12114/j.issn.1007-9572.2022.W0002
Special Issue: 指南/共识最新文章合辑
• Chinese Clinical Practice Guidelines in Primary Care • Previous Articles Next Articles
Received:2022-08-15
Revised:2023-01-19
Published:2023-05-05
Online:2023-01-31
Contact:
YE Zhikang
通讯作者:
叶志康
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.W0002
| 结局 | 强化降压组(%) | 常规降压组(%) | HR (95%CI) | 绝对风险差值(%) |
|---|---|---|---|---|
| 复合心血管事件(卒中、急性冠脉综合征、急性心力衰竭、冠状动脉血管重建术、心房颤动、心血管死亡) | 3.5 | 4.6 | 0.74 (0.60,0.92) | 1.1 |
| 卒中 | 1.1 | 1.7 | 0.67 (0.47,0.97) | 0.6 |
| 急性冠脉综合征 | 1.3 | 1.9 | 0.67 (0.47,0.94) | 0.6 |
| 急性心力衰竭 | 0.1 | 0.3 | 0.27 (0.08,0.98) | 0.2 |
| 冠状动脉血管重建术 | 0.5 | 0.7 | 0.69 (0.40,1.18) | 0.2 |
| 心房颤动 | 0.6 | 0.6 | 0.96 (0.55,1.68) | 0 |
| 心血管死亡 | 0.4 | 0.6 | 0.72 (0.39,1.32) | 0.2 |
| 全因死亡 | 1.6 | 1.5 | 1.11 (0.78,1.56) | 0.1 |
Table 1 Effect of intensive and standard blood pressure lowering on cardiovascular events
| 结局 | 强化降压组(%) | 常规降压组(%) | HR (95%CI) | 绝对风险差值(%) |
|---|---|---|---|---|
| 复合心血管事件(卒中、急性冠脉综合征、急性心力衰竭、冠状动脉血管重建术、心房颤动、心血管死亡) | 3.5 | 4.6 | 0.74 (0.60,0.92) | 1.1 |
| 卒中 | 1.1 | 1.7 | 0.67 (0.47,0.97) | 0.6 |
| 急性冠脉综合征 | 1.3 | 1.9 | 0.67 (0.47,0.94) | 0.6 |
| 急性心力衰竭 | 0.1 | 0.3 | 0.27 (0.08,0.98) | 0.2 |
| 冠状动脉血管重建术 | 0.5 | 0.7 | 0.69 (0.40,1.18) | 0.2 |
| 心房颤动 | 0.6 | 0.6 | 0.96 (0.55,1.68) | 0 |
| 心血管死亡 | 0.4 | 0.6 | 0.72 (0.39,1.32) | 0.2 |
| 全因死亡 | 1.6 | 1.5 | 1.11 (0.78,1.56) | 0.1 |
| [1] |
|
| [2] |
|
| [3] |
Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine[J]. JAMA,1992,268(17):2420-2425. DOI:10.1001/jama.1992.0349=0170092032.
|
| [4] |
|
| [5] |
Canadian Institutes of Health Research. Knowledge translation in health care:moving from evidence to practice[EB/OL].(2015-11-18)[2022-07-22].
|
| [6] |
|
| [7] |
|
| [8] |
World Health Organization. WHO handbook for guideline development,2nd edition[EB/OL]. (2014-12-18)[2022-07-28].
|
| [9] |
MacGRADE Centre Coordination. GIN-McMaster guideline development checklist[EB/OL]. [2022-07-20].
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
国际实践指南注册与透明化平台[EB/OL].(2022-07-09)[2022-07-28].
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and treatment of hypertension:a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension[J]. J Geriatr Cardiol,2019,16(3):182-241.DOI:10.11909/j.issn.1671-5411.2019.03.014.
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,detection,evaluation,and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. Hypertension,2018,71(6):e140-144. DOI:10.1161/hyp.0000000000000065.
|
| [42] |
|
| [43] |
|
| [1] | HEI Moran, MA Hui'e, XU Zecheng, YAN Shiyan, LI Ziyan, YANG Yi, JIN Jun, CHEN Zelin, GUO Yi, ZHAO Xue, ZHAO Tianyi. Comparison, Analysis and Considerations of Methods for Determining Clinical Questions in Domestic and International Clinical Practice Guideline Development Manuals [J]. Chinese General Practice, 2026, 29(18): 2554-2560. |
| [2] | GUO Jiao, ZHANG Gaojing, LIU Xincan. Quality Evaluation of TCM Clinical Practice Guidelines/Consensus: Based on Two Guideline Evaluation Tools [J]. Chinese General Practice, 2026, 29(15): 2100-2106. |
| [3] | LI Jing, JI Yan, SUN Liu, WANG Hanting, WU Jidong, LIU June. Summary of Best Evidence on the Management of Hearing Loss in Older Adults in Primary Health Care Settings [J]. Chinese General Practice, 2026, 29(13): 1713-1719. |
| [4] | ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long. Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [J]. Chinese General Practice, 2026, 29(09): 1194-1202. |
| [5] | LIU Dianchun, CHEN Xiaoying, WANG Qianyun, PAN Xingru, WEI Xuehan, WANG Bohong, WANG Ying, XUE Xue, LU Chunli. Evidence-based Pharmacological Investigation of the Clinical Practice and Rational Use of Metformin in Pre-diabetes Mellitus [J]. Chinese General Practice, 2026, 29(08): 1057-1068. |
| [6] | YU Hao, LIAO Peng, LUO Li. Digital Therapy for Stroke: Progress and Challenges from Screening to Intervention [J]. Chinese General Practice, 2026, 29(02): 240-246. |
| [7] | YIN Jiajia, YAO Li, ZHOU Zihan, LI Qinqin, WANG Tingrui, LIU Yan. Meta-analysis of Factors Influencing the Prevalence of Multimorbidity among the Elderly in Different Regions of China: a Comparative Study between the North and the South [J]. Chinese General Practice, 2025, 28(34): 4326-4336. |
| [8] | HE Yuling, LIN Meiqun, LUO Huiyu, HUANG Wenting, JIANG Liqin, ZHU Hongyu. Systematic Review of Guidelines for the Management of Patients with Cancer Pain [J]. Chinese General Practice, 2025, 28(33): 4199-4205. |
| [9] | ZHI Congcong, CHENG Yicheng, HUANG Zichen, WANG Xiaolong, LI Xue, ZHENG Lihua. Collection and Determination of Clinical Questions and Outcome Indicators Based on the Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Hemorrhoids (2025 Edition) [J]. Chinese General Practice, 2025, 28(32): 4089-4094. |
| [10] | MA Panpan, WANG Sijing, YOU Na, DING Dafa, LU Yibing. Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2679-2685. |
| [11] | MA Guifen, ZHANG Qian, SUN Jing. Interpretation of the Key Updates in the Latest Version of 2024 NCCN Clinical Practice Guidelines for Gastric Cancer [J]. Chinese General Practice, 2025, 28(14): 1681-1688. |
| [12] | GAO Yicheng, YU Zijin, CAO Rui, LIU Zhihan, FANG Rui, LI Yuanyuan, DENG Yingjie, XIANG Wenyuan, FEI Yutong. Thinking and Methodological Suggestions of Empirical Research in the Development of Clinical Practice Guidelines [J]. Chinese General Practice, 2025, 28(04): 402-406. |
| [13] | FENG Tianxiao, SUN Kai, QIN Xiaokuan, WANG Xu, BU Hanmei, ZHU Liguo, WEI Xu. Development Status, Challenges, and Strategies of Clinical Practice Guidelines in Traditional Chinese Medicine Orthopedics [J]. Chinese General Practice, 2024, 27(31): 3850-3856. |
| [14] | HE Jingyi, WANG Fang, SHUI Xiaoling, LI Ling, LIANG Qian. Efficacy of Non-pharmacological Interventions to Improve Perimenopausal Insomnia Symptoms: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(31): 3963-3974. |
| [15] | SU Guobin, LING Xitao, DUAN Ruolan, ZHANG La, XU Yuan, PENG Yu, HOU Haijing, LIU Xusheng, LU Fuhua. Selection of Therapeutic Drugs for COVID-19 Infection in Adults with Chronic Kidney Disease Based on Medical Evidence [J]. Chinese General Practice, 2023, 26(26): 3220-3229. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||